secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2026-06-09T11:16:42+00:00
Accession:  0001140361-26-024556
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian licenses WestGene's in vivo CAR-T LNP platform for autoimmune diseases; MG trial starts 2H2026
--------------------------------------------------------------------------------

- WestGene receives upfront payment and milestone-based payments; Cartesian gains exclusive rights to WestGene's tLNP platform for in vivo CAR-T.
- Phase 1 dose-escalation study of Descartes-08 mRNA delivered via WestGene's tLNPs in generalized myasthenia gravis expected to begin 2H 2026.
- In-human proof-of-concept data expected in 1H 2027; Cartesian plans to advance additional anti-BCMA CAR constructs and a BCMA TCE.
- WestGene's prior clinical data showed no DLTs, SAEs, ICANS, or IRRs in up to 14 doses per patient; only Grade 1 CRS observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000114036126024556/0001140361-26-024556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000114036126024556/ef20075770_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-024556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer